• Celebrate the holiday season with AcceGen’s highest discounts of the year. Merry Christmas and Happy New Year!

    Learn More

Home > Services > Cell & Gene Therapy Solution > Immune Cell Therapy Solution > CAR Molecule Design

CAR Molecule Design

CAR Molecule Design

CAR-T therapy, an increasing promising immunotherapy approach, is gaining significant momentum in the field of cancer treatment. It revolves around the genetic modification of T cells by introducing chimeric antigen receptors (CARs) to enhance their specificity and anti-tumor activity. CAR molecules are composed of several key components, including a signal peptide, an antibody-derived single-chain variable fragment (scFv), a hinge region, a transmembrane domain, a co-stimulatory molecule, and a CD3ζ signaling domain.

  • scFv screening: The selection of scFvs with high affinity and specificity is critical to the optimal function of Chimeric Antigen Receptors (CARs).
  • Linking groups: Various lengths of linkers between the variable heavy and light chains can enhance the flexibility of the CAR, which affects its binding affinity.
  • Hinge region optimization: The design of hinges with different lengths can enhance the spatial flexibility of the antigen binding region, leading to improved CAR function.
  • Co-stimulatory domain selection: The choice of co-stimulatory molecules, such as 4-1BB or CD28, can influence CAR activity and efficacy.
  • Reporter gene: The green fluorescent protein gene can be linked to a reporter gene to assess the successful transduction of the CAR.
CAR Molecule Design

Figure 1.CAR molecular structure[1]

AcceGen offers CAR design and construction services, as well as other specialized CAR strategies, to support research in combating cancer. Our services include biomarker identification, CAR generation, in vitro and in vivo assays, and clinical trials. With AcceGen’s expertise, you can access comprehensive support at various stages of CAR-T studies, accommodating different starting materials and research needs.

Application

  • Cancer Treatment: CAR-T therapy for leukemia, lymphoma, and solid tumors to target cancer cells.
  • Infectious Diseases: Targeting pathogens in viral and bacterial infections with CAR-T cell therapy.
  • Regenerative Medicine: Using CAR-T cells to enhance tissue regeneration and repair.
  • Combination Therapies: Integrating CAR-T with other treatments for synergistic effects and improved outcomes.

Reference

[1]. Zhang, C., Liu, J., Zhong, J.F. et al. Engineering CAR-T cells. Biomark Res 5, 22 (2017)

AcceGen Scroll Top Button